pulmonologyadvisor13h
Study Compares Single-Inhaler Triple Therapies for Treatment of COPD
For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.
19 drug approvals in 2024 that had 'big clinical impact,' according to GoodRx
GoodRx released a list of 19 of the most influential drugs and vaccines approved by the FDA in 2024 to treat a variety of ...
News Medical on MSN4d
Study finds no clinical advantage of budesonide inhaler over fluticasone in COPD
A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...
pulmonologyadvisor2d
COPD: Early Disease May Be Linked to Impaired FEV1/FVC Trajectories, Wheezing
Individuals with early-onset COPD and rapidly progressive pre-COPD frequently have a decades-long history of impaired ...
Hosted on MSN24y
AstraZeneca Expands Savings Program for Respiratory Medicines, Aiming to Ease Patient Costs
In a significant move aimed at enhancing access to essential respiratory care, AstraZeneca recently announced plans to broaden its savings programs across its entire US inhaled respiratory ...